Antihypertensive and hypolipidemic efficacy of triple fixed-dose combinations based on perindopril: INTEGRATION II study

The use of fixed-dose combinations for hypertension (HTN) has long been a routine clinical practice. Recently, special attention has been paid to multi-target fixed-dose combinations with the ability to reduce not only blood pressure (BP), but also low-density lipoprotein (LDL) levels. At the same time, there is not much evidence for this approach. Aim . To evaluate the antihypertensive and lipid-lowering effect of fixed-dose combinations based on perindopril. Material and methods . The INTEGRATION II study included 9777 patients (mean age 61,8±9,8 years) with HTN and dyslipidemia (DLP), who were prescribed a fixeddose antihypertensive combination of perindopril+amlodipine+indapamide (Co-Dalneva®) in combination with rosuvastatin (Roxera®) (n=5128) or a multi-target fixed-dose combination of perindopril+indapamide+rosuvastatin (Roxatenz-inda) (n=4649). Results . In the Co-Dalneva® + Roxera® group, a decrease in systolic BP from 164,9±13,8 mm Hg to 127,2±8,8 mm Hg was noted over 12‑week treatment, diastolic BP — from 94,2±10,0 mm Hg to 77,6±6,3 mm Hg; total cholesterol level decreased from 6,2±1,1 mmol/l to 4,3±0,8 mmol/l, and LDL level — from 3,6±1,0 mmol/l to 2,1±0,7 mmol/l. In the Roxatenz-inda group, over the same period, systolic BP decreased from 161,9±12,7 mm Hg to 126,2±8,3 mm Hg, while diastolic BP — from 94,5±9,5 mm Hg to 76,9±6,8 mm Hg. The total cholesterol level decreased from 6,3±1,1 mmol/l to 4,4±0,8 mmol/l; the LDL level — from 3,5±1,0 mmol/l to 2,1±0,6 mmol/l. Both physicians and patients rated Likert scale satisfaction with therapy as very good (4,75-4,8 out of 5), while the compliance according to the patient corresponds to high and highest. Conclusion . The results of the INTEGRATION II study demonstrated the efficacy and convenience of fixed-dose combinations of antihypertensive and lipid-lowering agents based on perindopril and rosuvastatin in practice. There are good tolerability and a high level of satisfaction with the treatment from both the patient’s and the phusician’s perspective.

Authors

Institutions

Publication Details

Journal
Russian Journal of Cardiology
Published
2025-08-08
DOI
https://doi.org/10.15829/1560-4071-2025-6418
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antihypertensive and hypolipidemic efficacy of triple fixed-dose combinations based on perindopril: INTEGRATION II study

А. О. Недошивин
Russian Journal of Cardiology
Blood Pressure and Hypertension Studies
article

Antihypertensive and hypolipidemic efficacy of triple fixed-dose combinations based on perindopril: INTEGRATION II study

А. О. Недошивин
article en

Abstract

The use of fixed-dose combinations for hypertension (HTN) has long been a routine clinical practice. Recently, special attention has been paid to multi-target fixed-dose combinations with the ability to reduce not only blood pressure (BP), but also low-density lipoprotein (LDL) levels. At the same time, there is not much evidence for this approach. Aim . To evaluate the antihypertensive and lipid-lowering effect of fixed-dose combinations based on perindopril. Material and methods . The INTEGRATION II study included 9777 patients (mean age 61,8±9,8 years) with HTN and dyslipidemia (DLP), who were prescribed a fixeddose antihypertensive combination of perindopril+amlodipine+indapamide (Co-Dalneva®) in combination with rosuvastatin (Roxera®) (n=5128) or a multi-target fixed-dose combination of perindopril+indapamide+rosuvastatin (Roxatenz-inda) (n=4649). Results . In the Co-Dalneva® + Roxera® group, a decrease in systolic BP from 164,9±13,8 mm Hg to 127,2±8,8 mm Hg was noted over 12‑week treatment, diastolic BP — from 94,2±10,0 mm Hg to 77,6±6,3 mm Hg; total cholesterol level decreased from 6,2±1,1 mmol/l to 4,3±0,8 mmol/l, and LDL level — from 3,6±1,0 mmol/l to 2,1±0,7 mmol/l. In the Roxatenz-inda group, over the same period, systolic BP decreased from 161,9±12,7 mm Hg to 126,2±8,3 mm Hg, while diastolic BP — from 94,5±9,5 mm Hg to 76,9±6,8 mm Hg. The total cholesterol level decreased from 6,3±1,1 mmol/l to 4,4±0,8 mmol/l; the LDL level — from 3,5±1,0 mmol/l to 2,1±0,6 mmol/l. Both physicians and patients rated Likert scale satisfaction with therapy as very good (4,75-4,8 out of 5), while the compliance according to the patient corresponds to high and highest. Conclusion . The results of the INTEGRATION II study demonstrated the efficacy and convenience of fixed-dose combinations of antihypertensive and lipid-lowering agents based on perindopril and rosuvastatin in practice. There are good tolerability and a high level of satisfaction with the treatment from both the patient’s and the phusician’s perspective.

Russian Journal of CardiologyVol. 30(6)
Federal Almazov North-West Medical Research Centre (RU)
Openalex Percentile: Top 68%
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Antihypertensive and hypolipidemic efficacy of triple fixed-dose combinations based on perindopril: INTEGRATION II study — А. О. Недошивин · Russian Journal of Cardiology (2025) | TGRS Research Map | TGRS